Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Exercise and Cardiovascular Response

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

Hypertension and Regulation of Blood Pressure

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...

Antihypertensive Drugs: Action of Diuretics

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...

Assessment of the Cardiovascular System I: Subjective Data

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Redefining Uric Acid and Cardiovascular Risk: Vascular Gout and Crystal-Driven Vascular Inflammation in Asymptomatic Hyperuricemia.

JACC. Asia·2026

Same author

Barriers and Associated Factors to Writing Case Reports Among Japanese General Medicine Physicians: A Cross-Sectional Study of the Japan Primary Care Association Members.

Journal of general and family medicine·2026

Same author

Big Data Analyses Using Health Care Records Can Reveal Epidemiologic Features of Kawasaki Disease in Japan: A Study Based on the National Database of Health Insurance Claims.

Journal of epidemiology·2026

Same author

Soluble uric acid enhances gouty inflammation via activating gene expression related to innate immune responses, M1 macrophage polarization and urate crystal phagocytosis in mouse macrophage-like cells: novel insights into its mechanisms from RNA sequencing.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

Same author

Differential associations of transient hyperuricemia and transient hypouricemia with annual changes in estimated glomerular filtration rate in healthy participants: an observational study.

BMC nephrology·2026

Same author

Endothelial cell-released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome.

Science translational medicine·2026

Search research articles

Related Experiment Video

Updated: May 28, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Hyperuricemia, A new cardiovascular risk.

Masanari Kuwabara¹, Ichiro Hisatome², Ryusuke Ae³

¹Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University Tochigi, Japan; Department of Cardiology, NHO Yonago Medical Center, Tottori, Japan.

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD

|February 12, 2025

Summary

High uric acid levels (hyperuricemia) are linked to cardiovascular disease. While lowering uric acid may reduce risk, current evidence on therapies like xanthine oxidase inhibitors is inconclusive, requiring further research.

Keywords:

Asymptomatic hyperuricemia Cardiovascular disease Gout Risk factor Uric acid

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

Related Experiment Videos

Last Updated: May 28, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

Area of Science:

Cardiovascular Medicine
Metabolic Disorders
Pharmacology

Background:

Hyperuricemia is a significant risk factor for cardiovascular diseases, including hypertension and heart failure.
Elevated uric acid levels contribute to inflammation and oxidative stress, impacting cellular processes.
The link between hyperuricemia and cardiovascular events is well-established, particularly in gout patients.

Purpose of the Study:

To review the association between hyperuricemia and cardiovascular diseases.
To explore the efficacy of uric acid-lowering therapies in mitigating cardiovascular events.
To discuss patient outcomes and the need for targeted treatments.

Main Methods:

Comprehensive literature review of PubMed sources.
Analysis of epidemiological studies and interventional trials.
Evaluation of xanthine oxidase inhibitors (e.g., allopurinol, febuxostat).

Main Results:

Consistent correlation between hyperuricemia and adverse cardiovascular outcomes observed.
Interventional trials with xanthine oxidase inhibitors yielded mixed results on cardiovascular event reduction.
Gender differences in uric acid levels noted, suggesting potential need for gender-specific risk assessment.

Conclusions:

The association between hyperuricemia and cardiovascular disease is strongly supported by evidence.
Current evidence on the benefits of uric acid-lowering therapies for cardiovascular events is inconclusive.
Future research should focus on personalized therapeutic strategies for high-risk patients.